Tango Therapeutics, Inc. (TNGX) NASDAQ
19.81
-5.06(-20.35%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
19.81
-5.06(-20.35%)
Currency In USD
| Previous Close | 24.87 |
| Open | 23.1 |
| Day High | 23.3 |
| Day Low | 19.34 |
| 52-Week High | 28.41 |
| 52-Week Low | 1.4 |
| Volume | 4.4M |
| Average Volume | 3.35M |
| Market Cap | 2.3B |
| PE | -23.87 |
| EPS | -0.83 |
| Moving Average 50 Days | 21.61 |
| Moving Average 200 Days | 12.19 |
| Change | -5.06 |
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 06, 2026 10:33 PM GMT
BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purch
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not inten
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 03, 2026 12:00 PM GMT
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenhei